Bellerophon Therapeutics, Inc. stock is up 327.5% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 December’s closed higher than November.
Bellerophon Therapeutics, Inc. focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform. InOpulse is in Phase 3 clinical trial for the. treatment of pulmonary hypertension associated with fibrotic interstitial lung disease.